TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06772545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia
Description: Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paravertebral Block
Description: Using an in-plane technique, the puncture needle was advanced from lateral to medial under real-time ultrasound guidance to the target paravertebral space, passing through the intercostal fascia, avoiding the parietal pleura, and positioning the needle tip superior to the costotransverse ligament. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: The plane of blockade and whether to perform a single or double injection technique were determined based on the incision location. Under real-time ultrasound guidance, the puncture needle was advanced to the target transversus abdominis plane. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was injected slowly in a fractionated manner while observing the local anesthetic spread to ensure effective blockade.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled intravenous analgesia (PCA)
Description: The patient-controlled analgesia (PCA) device was programmed to deliver bolus doses of 15 μg fentanyl, with a 10-minute lockout period and no background infusion. The PCA solution consisted of 1 mg fentanyl and 8 mg of tropisetron mixed in 100 mL of normal saline.
Study: NCT06773000

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XR™ Recovery Supplement
Description: Participants will receive a total daily dosage of 59.2 grams of XR™ Recovery Supplement orally, divided into two doses of 29.6 grams each (or two pouches). The dosing regimen will begin upon hospital admission and continue for three weeks post-operatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XR Carbohydrate Loading Supplement
Description: 2 packets of XR Carbohydrate Loading will be administered the evening before surgery and one packet on the day of surgery up to 2 hours prior to the scheduled operating time. The powder will be mixed with 14 oz of room temperature water only until dissolved then may be served over ice for desired temperature of consumption by the participant.
Study: NCT06772467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention (Reiki)
Description: Reiki was applied to this group twice a week for 4 weeks by a researcher who had a Reiki application certificate. Reiki sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Reiki is applied to the seven major chakras and many minor chakras in the body. The chakras are located in the centre of the body, on a vertical line, in the front and back of the body. In this study, Reiki was applied to the patients twice a week for 4 weeks. Reiki sessions were performed before haemodialysis and each session lasted approximately 35-40 minutes. The vital signs of the patients were measured and recorded 3 times: before each Reiki session, after the Reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT
Description: Emotional Freedom Technique (EFT) is a method that helps people manage their emotions and disturbing thoughts, helping to reduce their stress and anxiety. EFT is also called tapping.~EFT sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Patients received 8 sessions of EFT. The vital signs of the patients were measured and recorded 3 times: before each EFT session, after the reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale.
Study: NCT06770595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding positions and attachment practice.
Description: Breastfeeding clinical demonstration is a method of presentation of skills that shows how a particular procedure is performed in position and attachment breastfeeding. Respondents in this group will receive education provided face-to-face once with a duration of 40 minutes, with the following details: first, 25 minutes of education about breastfeeding position and attachment. In this case, the lactation counselor first explains the correct position and attachment for breastfeeding. Respondents were asked to carry out a practical simulation regarding the correct breastfeeding position and attachment using a doll, in this case, the lactation counselor will assess how the mother is positioned and attached. second, 10 minutes of education about swollen breasts and how to deal with them. third, a 10-minute question and answer session related to the educational material provided.
Study: NCT06771310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: The exercise-training program will be consisted of 10 minutes warming up, 30 minutes of treadmill walking, and 10 min cooling down three times per week.~Warming up: It will be in the form of stretching of muscle groups for 10 minutes (3-5 stretch for the key muscle group (iliopsoas muscle, gluteus maximus ,quadriceps ,tibialis anterior , calf muscle, hold for 20-30 seconds), before the actual aerobic training session.~Actual session: Participants will receive aerobic exercises in the form of Moderate aerobic exercise training in the form of 30 min of treadmill walking and corresponding to a target heart rate of 65% to 75% of HR max (Maximum HR = 220 - Age ) to be gradually achieved and maintained throughout the training program.~Cooling down: It will be in the form of a treadmill walking at very slow speed for ten minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The participants will be asked to assume standing position then to flex back to reach its maximum point.~* Two bands, 1 on each side of the lumbar spine, will be applied vertically from the lower posterior iliac crest region to the upper twelfth rib region, with inhibition technique.~* The remaining 2 bands will be attached horizontally, with space correction technique.~* All 4 bands will be placed to allow for 50% longitudinal stretching. The stretching directions for the vertical and horizontal applications were bottom-up and sideways, respectively.
Study: NCT06774560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/Cam milled onlays
Description: The digital workflow in dentistry has proven in the past decades to be a time-efficient, multifunctional, effortless, and accessible approach. The inherited shortages milling machines represented by the incapability to produce accurate complex hollow structures may give preference to modern 3D ceramic printing.~Computer-aided-design/computer-aided-manufacturing (CAD/CAM) in dentistry is a digital subtractive approach for manufacturing indirect restorations. Nevertheless, waste materials and milling burs wearing are considered as key disadvantages of CAD/CAM technology, and are the main drive to improve 3D printing technology (additive manufacturing) as the latter has shown considerable efficiency in minimising wasted materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed onlays
Description: 3D printing technologies are developing more intensively in dentistry as this technology has the capacity to produce shapes or models with high accuracy and in a short time. This method of fabrication takes less time and money and saves on materials compared to CAD/CAM.~Although it seems that digital manufacturing technology has made great changes in the restorative dentistry field, this technology is still not fully in use. This is possibly because of the lack of studies and research on this technology, particularly in terms of clinical performance and patient-centred outcomes. 3D printing technologies are novel technologies with a lack of research; therefore, the processing of 3D printing materials is still controversial.
Study: NCT06772077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment with ATLAS2030
Description: 10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.
Study: NCT06770777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiered whole health support for people living with COPD
Description: The website design allows study participants to choose the intervention tier(s) that meets their needs. There are three tiers from Tier 1: Information only, Tier 2 Reflective Writing, and Tier 3 LCSW Psychotherapeutic Intervention. Participants will also be able to choose multiple tiers if they are interested in continuing their participation. First Tier: The website offers standardized information about COPD care, healthcare navigation, and whole-person care. Information includes symptom management, disease progression and trajectory, healthcare navigation concepts, and directs people to the VA website with information about whole-person care. Second Tier: If participants choose, they can also select writing prompts with opportunities to reflect on their whole-person care and adjustment to illness. Third Tier: People living with COPD can also select to have asynchronous interaction with a licensed clinical social worker providing the narrative-based psychotherapeutic intervention.
Study: NCT06511037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging
Description: Given IV
Study: NCT04828577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Time Neurofeedback
Description: Participants receive feedback from own brain activity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Idealized/Sham Neurofeedback
Description: Participants receive idealized feedback not related to their own brain activity.
Study: NCT05932914

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: Standard transjugular liver biopsy under moderate sedation
Study: NCT06544291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 300mg
Description: 3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 300mg
Description: 3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 300mg
Description: 3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT05662670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ13404 tablets
Description: Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied.
Study: NCT04805489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask
Description: The sequence of mask wearing will be done by drawing lots, in double blind. Only the nurse will be informed of the mask sequence. The doctor will take measurements without seeing the type of mask placed between the athlete's face and the VO2 mask.~The patient will not know which mask will be applied. He will have been informed that he will test three masks (a so-called high-tech mask which will in fact be without a mask, a surgical mask and a general public mask). When the mask is put on, the athlete's eyes will be closed, the sequence without a mask, presented to the subject as a high-tech mask, will be done with a mask that will be put on like a surgical mask or a mask for the general public, except that it will be hollowed out in its center.~The effort tests will be done on a carpet with a filter called COVID on the VO2 masks.
Study: NCT05139511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Same procedure but without energy
Study: NCT04658940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQBlate® Force Sensing Ablation System
Description: Percutaneous catheter ablation of the cavotricuspid isthmus
Study: NCT06544291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 600mg
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT06353022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22
Study: NCT06544291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 600mg
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD 600mg
Description: 6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 0mg
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 0mg
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0mg
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT06227182

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound with surface electromyography and dynamometry
Description: The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound with surface electromyography and dynamometry
Description: The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan
Description: In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
Study: NCT05424783

Intervention type: OTHER
Intervention: Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Description: The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.
Study: NCT06240364

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron extract (Crocus sativus)
Description: Daily intake of one tablet for 84 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of one tablet for 84 days.
Study: NCT06271525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cupping therapy
Description: All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~1. -Primary sucking~2. -Scarification 3- Bloodletting 4-Removal~5 -Dressing
Study: NCT05231837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Fee Waiver
Description: Fees are waived for youth sports programs at the park and recreation center

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fee Waiver Plus Intensive Outreach
Description: Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
Study: NCT05218798

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardio Respiratory Fitness testing
Description: In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardio Respiratory Fitness testing
Description: In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardio Respiratory Fitness testing
Description: In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardio Respiratory Fitness testing
Description: In a randomized cross over designed study, we will measure Vo2max by using different tests:~1. Continous Treadmill Running Test~2. Continous 2-mile run test~3. 30-15 Intermittent Fitness Test - first trial and second trial
Study: NCT05662618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous selective arteriography of peripheral arteries
Description: Treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery with rapamycin coated balloon catheter.
Study: NCT05328180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.